Ozempic vs Wegovy

Ozempic (semaglutide) was reviewed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Wegovy (semaglutide) was reviewed for weight management and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

Ozempic's review documents highlight a mean half-life of 155 hours in subjects with T2D. Wegovy's review documents show that 88.47% of participants achieved a body weight reduction of ≥5%, and the estimated treatment difference in body weight change versus placebo was -14.81.

The trials for Ozempic and Wegovy were distinct, with different designs, patient populations, and timepoints, reflecting their respective indications. Ozempic focused on glycemic control and cardiovascular risk reduction in type 2 diabetes, while Wegovy focused on weight management and cardiovascular risk reduction in individuals with obesity or overweight. The figures presented are from separate trials and should not be compared directly; neither drug is presented as superior.